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Incidenceandclinicalimplicationofnosocomialinfections
associated with implantable biomaterials – catheters,
ventilator-associated pneumonia, urinary tract infections
Inzidenz und klinische Folgen implantatassoziierter nosokomialer
Infektionen – Blutgefäßkatheter, beatmungsassoziierte Pneumonie,
Harnwegskatheter
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patients, pneumonia in patients intubated on a ventilator and bacter-
aemia related to intravascular catheter use. At least half of all cases of
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intravasculardevices,catheter-relatedurinarytractinfection,ventilator-
associated infection, and infections of other implantable medical
devices.
Raising awareness for infection associated with implanted medical
devices, teaching and training skills of staff, and establishment of sur-
veillance systems monitoring device-related infection seem to be the
principal strategies used to achieve reduction and prevention of such
infections. The intelligent use of suitable antiseptics in combination
with medical devices may further support reduction and prevention of
such infections. In addition to reducing the adverse clinical outcomes
relatedwiththeseinfections,suchreductionmaysubstantiallydecrease
theeconomicburdencausedbydevice-relatedinfectionforhealthcare
systems.
Keywords: hospital-acquired infections, medical device associated
infections,catheterrelatedbloodstreaminfections,ventilator-associated
pneumonia, urinary tract infections, prosthetic joint infections, pace
maker infections, vascular graft infections, prevention, surveillance
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Review Article OPEN ACCESSZusammenfassung
Nosokomiale Infektionen sind in industrialisierten Ländern heute die
vierthäufigste Todesursache und schon allein deshalb eine große Her-
ausforderung.EinTeildesProblemsgehtaufdiezunehmendeHäufigkeit
des Einsatzes invasiver Medizinprodukte (MP) zurück, da unter Anwe-
senheiteinesMPeinesignifikantgeringereAnzahlvonMikroorganismen
erforderlich ist, um eine Infektion zu begünstigen. Die häufigsten und
häufig folgenschweren nosokomialen Infektionen sind postoperative
WundinfektionensowieInfektionenimZusammenhangmiteingesetzten
oder implantierten MP wie Katheter-assoziierte Harnwegsinfektionen,
Bakteriämien oder Beatmungs-assoziierte Pneumonien. Mindestens
dieHälfte,wennnichtweitmehr,dieserInfektionensindmitdemEinsatz
von MP vergesellschaftet. Moderne medizinische und chirurgische Be-
handlungsmethoden haben das Erfordernis des Einsatzes implantier-
barer MP deutlich gesteigert. Dadurch sind große Fortschritte in den
Behandlungsmöglichkeiten, in der Steigerung der Lebensqualität und
in der Rettung von Patienten eröffnet worden. Solche MP können nur
kurz, intermittierend, oder über Monate und sogar Jahre im Körper
verbleiben. Werden sie mit Mikroorganismen kontaminiert, können
diese das MP in einer Geschwindigkeit von bis zu 0,5 cm pro Stunde
besiedeln. Als Folge können ausgehend von einer geringen initialen
Kontaminationszahlschoninnerhalbvon24hdickeBiofilmeentstehen,
die die gesamte Fläche des MP einnehmen können.
Das Ziel der vorliegenden Übersichtsarbeit ist es, die bestehende Lite-
ratur hinsichtlich Ursachen, Häufigkeit, und präventiver Maßnahmen
gegen MP-assoziierte Infektionen zu analysieren.
Gesteigerte Bewusstseinsbildung für den Zusammenhang zwischen
implantiertenMPundInfektionen,SchulungundÜbungderFertigkeiten
hinsichtlichUmgang,sowiedieEtablierungvonSurveillanceSystemen,
die den Verbrauch und die mit MP vergesellschafteten Infektionen
monitieren, scheinen die Eckpfeiler der Prävention MP-assoziierter In-
fektionen zu sein. Der Einsatz sinnvoll ausgewählter und richtig einge-
setzter Antiseptika kann einen zusätzlichen Beitrag zur Reduktion MP-
assoziierter Infektionen beitragen. Neben der Reduktion klinischer Ne-
benwirkungen kann die Reduktion MP-assoziierter Infektionen einen
Beitrag zur Steigerung der Lebensqualität und Verbesserung der Be-
handlungsqualität leisten, aber auch zu signifikanten wirtschaftlichen
Einsparungen im Gesundheitssystem beitragen.
Schlüsselwörter: Krankenhaus-erworbene Infektionen,
Medizinprodukt-assoziierte Infektionen, Katheter-assoziierte
Blutstrominfektionen, beatmungsassoziierte Pneumonie,
Harnwegsinfektionen, Gelenkendoprotheseninfektionen,
Herzschrittmacher-Infektionen,Gefäßprothesen-Infektionen,Prävention,
Surveillance
Introduction
Health care associated infections, the fourth leading
cause of disease in industrialised countries, are a major
health issue. Such nosocomial (hospital-acquired) infec-
tions are today by far the most common complications
affecting hospitalized patients. Based on a conservative
estimate,10%oftheEuropeanpopulationishospitalised
each year. Thereof, it is assumed that 5% (3.8% on a
general ward, 15.3% in intensive care units) acquire at
least one nosocomial infection. Based on these figures,
it can be estimated that some 1.75 million hospitalised
patients are affected annually in Europe. Assuming a
conservative 10% attributable mortality rate, this equals
175,000 deaths from nosocomial infections every year
[1]. The results of the EPIC study suggest even greater
numbers of affected patients [2]. Reports from the US
indicatethatnosocomialinfectionsaccountsfor2million
infections and 90,000 deaths per year [3]. In 2000, the
USCentersforDiseaseControlandPreventionestimated
the total costs of nosocomial infections to be in excess
of5billionUS$.Thesefiguresdonottakeinaccountthe
vast cost of treating these infections and disabilities
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proximately2.4billion€arespentannuallyfortreatment
of these infections [5]. The impact on direct costs of
medical care and the increase of healthy life condition
together with loss of productivity due to early death or
chronic illness has not been estimated [6].
While in Europe and developed countries the number of
patients treated in hospitals and average lengths of stay
decreased during recent decades, hospital acquired in-
fections have increased. In addition, the consequences
ofhospitalacquiredinfectionshavebecomemoresevere
than a decade ago, also because of increasingly highly
vulnerable patients together with emerging of antibiotic-
resistant microbes, especially Staphylococcus aureus,
EnterococcusspeciesandGram-negativemicroorganisms
producing extended spectrum beta-lactamases (ESBL)
[7], [8], [9]. The situation is getting even worse because
in the next future there will be very few new antibiotics
under development [10].
Health care providers, clinical epidemiologists, clinicians
and hospital administrators are becoming increasingly
concerned with the problem of preventable health care
associated infections as infected medical devices are a
common source of nosocomial infections and contribute
to substantial morbidity and mortality. Crude mortality
ratesassociatedwithnosocomialinfectionsduetodevice-
related infections vary from 12–80%, dependent on the
populationstudiesandthedefinitionsused[11].Attempts
to assess attributable mortality rates are controversial
since patients who need medical devices and develop
nosocomial infections are generally sicker and have a
greater risk of death than patients who do not [12].
Moreover, with the introduction of the diagnostic-related
Groups system (DRGs) hospital acquired infections are
generally not remunerable.
The most significant hospital-acquired infections, based
on frequency and potential severity, are those related to
procedures e.g. surgical site infections and medical
devices, including urinary tract infection in catheterized
patients,pneumoniainpatientsintubatedonaventilator
and bacteraemia related to intravascular catheter use.
At least half of all cases of nosocomial infections are as-
sociated with medical devices [13], [14], [15], [16]. It
became clear since Elek and Conen demonstrated 1957
that the presence of a foreign body significantly reduces
thenumberofbacteriarequiredtoproduceinfection[17].
Microorganisms gain access to the body by multiple
pathogeneticpathways.Theyaresignificantbothfortheir
potentialseverity(illnessand/ordeath),butalsobecause
of the potential preventability of these infections. Beside
decreased patients’ host defence and colonisation of
mucous membranes by pathogenic microorganisms, the
disruption of the integrity of the surface of the body
caused by implantable medical devices and direct and
indirect access of microorganisms into the respiratory
tract,theurogenitaltract,bloodstreamandcerebrospinal
space are major routes [18]. Despite the sometimes low
virulenceofinvadingmicroorganismsinvolved,thebodies
own defence mechanisms are unable to eradicate the
organisms effectively even when the host is fully immun-
ocompetent.However,underlyingdisorderslikemalignan-
cies, diabetes and agents impairing host defence mech-
anisms e.g. administration of corticosteroids, antineo-
plasticagentsandparenteralnutritionarewellrecognized
risk factors. Risk for nosocomial infections is, among
others, associated with duration of hospital stay, type of
wardandintensityofcare[19],[20],[21],[22].Multivari-
ate analyses revealed that implantable medical devices
as a major independent risk factor present on more than
half of patients with positive blood cultures [15], [23].
Data from 498,998 patients analyzed in a report from
the National Nosocomial Infection Surveillance (NNIS)
system indicate that nosocomial urinary tract infections
areamongthemostcommoncausesofnosocomialinfec-
tions, in 97% of cases associated with urinary catheters,
87% of primary bloodstream infections are associated
with central lines [23]. As bacterial meningitis became a
rare event during the last decade, ventriculitis and men-
ingitis now are caused in more than 90% of patients due
to external and internal implanted medical devices [24].
Modernmedicalandsurgicalpracticeshaveincreasingly
utilized implantable medical devices of various kinds.
Such devices may be utilized only short-time or intermit-
tently, for months, years or permanently. They improve
the therapeutic outcome, save human lives and greatly
enhance the quality of life of these patients. However,
plastic devices are easily colonized with bacteria and
fungi [24]. Multi-resistant nosocomial pathogens are the
most common organisms colonizing the outer and inner
surface of catheters and proliferate on the surface at a
rate of up to 0.5 cm per hour. A thick biofilm is formed
within 24 hours on the entire surface of these plastic
devices once inoculated with a small number of bacteria
[25].
The quoted incidence of nosocomial infection varies ac-
cording to the medical device involved, the setting i.e.
the type of hospital or intensive care unit, the population
of patients the precise definition used [26].
Infections of intravascular devices
Vascular accesses are used for administration of fluids
and electrolytes, blood products, medication, parenteral
nutrition or haemodynamic monitoring. They are an es-
sential tool of modern medicine. Regrettably, vascular
access devices are also associated with substantial and
generally underappreciated potential for producing
iatrogenic disease, particularly bloodstream infection. In
order to be able to compare the numerous clinical and
epidemiologicalstudies,definitionsofthecorrectnomen-
clature of device related infections and type of infection
is important [27], [28].
Local Infections
Foreign body related infections can be defined as local
infection at the port of entry without signs of systemic
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tions i.e. bloodstream infections. However, not each
isolation of a micro-organism from a catheter surface in-
dicates a relevant infection requiring therapeutic atten-
tion. Colonization of medical devices without infection is
possible.
Localized catheter colonization
Defines as significant growth of a microorganisms (>15
CFU)fromthecathetertip,subcutaneoussegmentofthe
catheter or catheter hub. This has to be distinguished
from local infections with clinical symptoms and signs of
an inflammatory process.
Exit site infections
An erythema or induration within 2 cm of the catheter
exit site is observed in absence of a concomitant blood-
stream infection and without purulent discharge. Clinical
exit site infection of tunnel infection means tenderness,
erythaema or site induration >2 cm around the catheter
site of along the subcutaneous tract of a tunnelled cath-
eter in absence of a concomitant bloodstream infection.
Pocket infection
Apocketinfectionisdefinedaspurulentdischargeofthe
subcutaneouspocketofatotallyimplantedintravascular
catheterthatmayormaynotbeassociatedwithspontan-
eous rupture and drainage or necrosis of the overlying
skin, in the absence of concomitant bloodstream infec-
tion.
Central venous catheter infections
Central venous catheters have been shown to be an im-
portant independent risk factor for nosocomial blood-
stream infection (BSI) equivalent to septicaemia: In clin-
ical studies, septicaemia is considered to be catheter
associatedwhenthepathogen,isolatedfromthecatheter
tip, the hub or the infusion solution is identical to the or-
ganism isolated in at least one peripheral blood culture.
According to the definitions of the national nosocomial
infection surveillance (NNIS) system of the CDC, blood-
stream infections are always considered to be device re-
lated if there is a time link with the use of an i.v. catheter
[4]. BSI is considered to be catheter associated if a
centralvenouscatheter(CVC)hasbeeninserted48hours
before the symptoms of infection occurred or if it is still
in place [29].
Central venous catheters are indispensable in the man-
agement of critically ill patients, e.g. for administration
of large amounts of fluids and electrolytes, drugs, par-
enteral nutrition and blood components. The history of
central venous cannulation starts in 1929 when a young
surgical resident inserted a cannula into his antecubital
vein. By watching the catheter’s progress in a mirror held
in front of a fluoroscope screen, he passed it for 65 cm
forwarduptohisauricle.Bythismaneuverthetechnique
of vascular catheterization was developed [30]. Twenty-
seven years later, in 1956, Werner Forssmann was
awarded together with André Cournand and Dickson
Richards, who put Forssmann’s procedure 1941 into
practice, the Nobel Prize.
In1952Aubaniacdescribedhisexperiencesofpuncturing
the subclavian vein. Since that time central venous
catheterization has developed to a standard procedure
in routine clinical practice [31]. In critical care and
emergencymedicineintravascularcathetershavebecome
integral to the practice of modern medicine.
However, while central venous catheters make intensive
care for critically ill patients possible, they are also asso-
ciated with serious complications, the most common of
which is infection. Intravascular catheters are one of the
most common causes of nosocomial bacteremia and
catheter-related bloodstream infection affects over
250,000 patients per year in the United States [32]. The
use of such devices account for an estimated 90% of all
nosocomialbloodstreaminfections[33],andtheattribut-
able mortality in ICU patients is an estimated 35% for
each infection [34].
Because of this, the decision to use central venous
catheters must always be made on the basis of a strict
risk-benefitassessmentandforeachpatientthereasons
for catheterization must be given careful consideration.
Central venous catheters: short term
Short term, non cuffed central venous catheters may
becomeinfectedfrommultiplesources:Themostobvious
sourceofinfectionisthecutaneousoriginofmicroorgan-
isms that invade the percutaneous tract extraluminally
at the time the catheter is inserted or the days following
insertion – probably facilitated by capillary action [35],
[36]. There is a strong concordance between organisms
present on skin surrounding the catheter insertion site
and organisms producing septicaemia. After the fourth
day catheter contamination and BSI originates from the
hub and the catheters are contaminated intralumenal
[37].Withsurgicallyimplantedcuffedlong-termHickman
or Broviac catheters, microorganisms colonizing the hub
andlumenarethemostimportantsourceofbloodstream
infections.Thereisasubstantialvariableofbloodstream
infectionsinmulti-lumencathetersoriginatingfromdiffer-
ent lumina: the large bore lumen with a flow of 100
ml/hourormoreistheleastlikelylumentobethesource
of a BSI although most frequently used for obtaining
quantitativebloodcultures.Smallluminawithaflowrate
of a few millilitres per hour, frequently used for adminis-
tration of catecholamines which favour bacterial growth
and biofilm formation are at a substantially higher risk
forinfectionalthoughinfrequentlyusedforbloodcultures
[38]. Antibiotics administered through one of the smaller
lumina in contrast prevent contamination and infection
[39].
A further source of infection is a contaminated infusate
where large numbers of bacteria gain access intralumin-
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of an epidemic line related BSI [39]. Implantable devices
can also become infected from remote unrelated sites
of infection but evidence suggests that this is a rather
uncommon cause of infection [40].
The incidence of catheter related sepsis is a matter of
greatcontroversyandsubstantialdifferencesinincidence
have been reported. Prospective studies of short term,
non-cuffed single or multi-lumen catheters inserted per-
cutaneouslyintothesubclavianorjugularveinhavefound
rates of catheter related septicaemia in a range of 3–5%
with rates up to 14% in various hospitals. Risk factors for
BSI are observed in patients with impaired host defence
mechanisms e.g. premature and newborn infants, pa-
tients with severe burn injuries, diabetes, and corticost-
eroid treatment. In patients with haemato-oncologic ma-
lignancies a frequency of up to 16% of patients with
device related BSI has been reported [41], [42], [43],
[44], [45]. These vast differences can be attributed to
the type of patient treated in an intensive care unit, the
underlying disorders and drugs administered. It has to
be emphasized that the duration of CVCs in this group of
patients is generally longer [46]. A lower than average
riskseemstobeobservedinpatientsreceivingantibiotic
for some indication [47]. However there is insufficient
evidence from randomised trials to support or refute the
use of prophylactic antibiotics when umbilical venous
catheters are inserted in newborn infants. There is no
evidence to support or refute continuing antibiotics once
initial cultures rule out infection in newborn infants with
umbilical venous catheters [48].
Inpaediatricintensivecareunitstheincidenceofcatheter
related BSI has been reported from 5.5/1,000 catheter
days to 10.3/1,000 catheter days [48], [49], [50], [51].
In a survey performed in 74 paediatric intensive care
unitsintheUSameanof7.4/1,000catheterdays(range
1.3 and 11.9% of patients) has been observed. Higher
rates have been reported in premature and newborn in-
fants with 12.8/1,000 catheter days [52].
The source of the data is of crucial importance. Differ-
ences in incidence are seen between clinical prevention
studies and data derived from surveillance studies. Dif-
ferences in the incidence data are related to the type of
study (prospective versus retrospective investigation)
[53]. Surveillance data derived from 14% of hospitals of
acountryobtainedbyvoluntaryreportingcannotlegitim-
ately extrapolated to the entire population. It has to be
emphasized, that in field trials catheter associated BSI
are substantially more frequent than commonly antici-
pated and described in literature. Data from all patients
admitted to any Austrian intensive care unit during one
half year have been collected by Hiesmayr et al. Their
unpublished study involves 3,003 patients with a total
of29,473devicedaysandameanof9.81catheterdays.
For central venous catheters an average of 6.9 infec-
tions/1,000 device days (6% of patients) have been ob-
served by clinical criteria, 15.2/1,000 device days and
14.9% of patients by microbiologic criteria. Variations
between 0 and 32/1,000 catheter days were observed
in CVC. With arterial catheters an average of 2.4/1,000
catheter days was reported [54].
An increased incidence is seen with multi-lumen versus
single lumen catheters, duration of catheter placement
and the type of infusion solution i.e. physiological saline
versus total parenteral nutrition containing amino acids
and fat emulsions [55].
Animportantvariableisalsothenumberofmanipulation
at the hub, the fixation of the catheter and the dressing
applied. Investigations have shown that consistent and
high level of asepsis during catheter insertion and main-
tenance provided by special i.v. care teams have been
associated with substantially lower rates of catheter re-
lated infections [56]. In accordance to this understaffing
has also been identified as an independent risk factor
[57].
Mortality attributed to CVCs ranges between 3 and 33%
withanaverageof20%[58],[59],[60],[61].Again,these
figures depend on a number of factors like the type of
study, diagnosis and definition of the severity of nosoco-
mial sepsis and the underlying disorders. Soufir et al.
showed crude mortality rates of 50% and 21%, respect-
ively, in patients with and without catheter related sep-
ticaemia and this figures remained valid with mortality
adjustedforadmissionprognosticfactors.However,when
adjusted for severity scores measured during the week
before infection, catheter related septicaemia was no
longer associated with increased mortality [62].
Central venous catheters: intermediate
(Sheldon)
Catheter-related infections have been identified as a
majorcauseofmorbidityandmortalityinpatientsreceiv-
ing haemodialysis independently in a number of studies
[63], [64], [65]. There are particular risk factors originat-
ing from Sheldon catheters used for haemodialysis until
maturation of a Cimino shunt. The mean duration of
catheter placement is therefore with 6–12 weeks longer
thantheusualplacementofshorttermCVCs.Thedouble
lumen catheter with a diameter maintaining a blood flow
of at least 150 ml/min is placed into the jugular vein.
There is generally a shorter subcutaneous tunnel and a
stiffer material than used with short term central venous
catheters. This enables easy penetration of microorgan-
isms along the catheter path and also exerts damage to
the great veins. Catheterization of the internal jugular
vein is associated with longer catheter survival when
compared to the femoral vein. The likelihood of catheter-
related bacteraemia ranges between 2.1% and 48% at
6 months. The frequency of vascular access infection
was 3.1 per 100 patient-months and varied from 0.6 for
fistulas to 10.1/100 catheter days for temporary cath-
eters [66]. Variable reporting systems are also a matter
of discrepancies. Taylor et al. reported on the incidence
ofbloodstreaminfectioninmulti-centreinceptioncohorts
of haemodialysis patients. A total of 527 patients were
recruited and underwent 31,268 haemodialysis proced-
ures during a 6-month follow-up. There were 96 blood-
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patients suffered from a catheter related bloodstream
infection (CRBI) (11.97/1,000 days, 28.81/1,000 hae-
modialysisprocedures),yieldingarelativeriskofinfection
of 3.33 (95% CI, 2.12–5.24) for patients with a previous
bloodstream infection and 1.56 (95% CI, 1.02–2.38) for
patients on continuing haemodialysis [67]. Survival ana-
lysis revealed that compared to arterio-venous fistula
vascularaccess,therelativeriskofbloodstreaminfection
in patients was 1.47 (95% CI, 0.36–5.96) for arterio-
venous grafts, 8.49 (95% CI, 3.03–23.78) for cuffed
centralvenouscatheters,and9.87(95%CI,3.46–28.20)
for un-cuffed central venous catheters [68]. The regres-
sion model of the case-control study identified earlier
bloodstream infection (6.58 d), poor patient hygiene
(3.48 d), and superficial access-site infection (4.36 d) as
additional risk factors. In general, the frequency of mal-
function of a haemodialysis associated vascular device
affects between 15 and 36% of patients.
The majority of cases requiring long-term continuous
haemofiltration (CHF) are complicated with a variety of
infections, it is difficult to control infections associated
with haemodialysis catheters separately from infections
of other types. Systemic infection control should serve
as a strategy finally leading to successful control of
catheter-related infection.
InastudyconductedbyAbdulrahmanetal.atotalof109
infections, for a rate of 11.32/1,000 dialysis sessions
were identified, 23 involved permanent fistulae or grafts
(4.23/1,000); 18 involved permanent-tunnelled central
catheterinfections(10.1/1,000dialysis);and68involved
temporary-catheter infections (28.23/1,000 dialyses)
[69].
Almost one quarter of population on haemodialysis re-
main catheter dependent. Despite concerted efforts,
there are very long delays in achieving a usable perman-
ent access in individual patients, attributable to delays
inbothsurgicalaccessplacementandaccessmaturation.
An antibiotic lock of Sheldon-catheters in intervals
between haemodialysis procedures has been shown to
reduce the incidence of sepsis and increase the success
ofsystemicantibiotictreatmentofinlinesepsis.Therate
ofvascularaccessinfectionisgenerally3per100patient-
months and varies from 0.6 for fistulas to 10.1 for tem-
porary catheters [70], [71], [72]. Prophylactic measures
include antibiotic locks with various antibiotic regimens
[73].
Peripheral venous catheters infections
At peripheral venous catheters catheter related phlebitis
is a frequent problem. The rate of phlebitis varies in a
broad range between 2.3 and 40%. The intravenous
application of phlebitis-inducing medication and
physiochemical and mechanical irritation of the vessel
wall by various materials plays a major role and contrib-
utes to contamination with bacterial microorganisms.
Steelneedlesaregenerallylesswelltoleratedthansmall
Teflon or polyurethane catheters now in use. Substantial
improvements have been achieved with newer plastic
materials regarding surface properties which have been
identified to play a crucial role for thrombogenesis and
infection [29].
High risk patients for infectious phlebitis were observed
with haemato-oncologic malignancies [74]. An individual
biologicvulnerabilityofindividualpatientshasbeenfound
while the duration of placement of a peripheral catheter
contributed less. An important factor was the level of
technical skill for placement of peripheral catheters.
Meticulous hygiene measures, less mechanical irritation
and careful management by members of i.v. teams tend
to have a lower incidence of phlebitis and infection than
placement by less skilled personnel [75]. The choice of
an optimal placement site is viewed controversial al-
though placement in the lower extremity is connected
with increased risk for thrombophlebitis and infection
[76]. Bloodstream infections and positive bloodcultures
arewith0.08%–0.2%aratherinfrequenteventincontrast
to placement of a central venous catheter as an infected
thrombus is frequently a local phenomenon [77], [78].
InfectionscausedbyTenckhofCatheters
used for peritoneal dialysis
Peritoneal dialysis (PD) catheter insertion can be accom-
plished by any one of three techniques. These include
dissective or surgical, the blind or modified Seldinger,
and laparoscopic techniques. The dissective technique
solely utilized by surgeons, places the catheter by mini-
laparotomy under general anaesthesia. In the blind or
modified Seldinger technique a needle is inserted into
theabdomen,aguide-wireplaced,atractdilatedandthe
catheter is inserted through a split-sheath, all without
visualization of the peritoneal cavity [79]. Of the various
laparoscopes, peritoneoscopic insertion uses a small
opticalperitoneoscopefordirectinspectionoftheperiton-
eal cavity and identification of a suitable site for the in-
traperitonealportionofthecatheter.Hence,ofthevarious
techniques, only the insertion by direct pertoneoscopy
allows the direct visualization of the intraperitoneal
structures. This technique can be easily used by nephro-
logists as well as surgeons. Peritoneoscopic placement
varies from traditional laparoscopic techniques by using
a much smaller scope (2.2 mm diameter) and puncture
size, only one peritoneal puncture site, a device to ad-
vancethecuffintothemusculature,airintheperitoneum
ratherthanCO2,andlocalanaesthesiaratherthangeneral
anaesthesia.Prospectiverandomizedandnonrandomized
studies have shown that peritoneal dialysis catheters
peritoneoscopically placed by nephrologists have less
incidence of complications (infection, exit site leak) and
longer catheter survival rates than those inserted surgic-
ally [80], [81].
Boehm at al. reported an incidence of 1:14.6 months or
0.82/patient per year in children, indicating that more
than every second patient was infected. Potential risk
factors were significantly correlated with two or more of
the outcome indices: age, APD treatment, exit-site infec-
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[82]. Lerner et al. reported 964 episodes of peritonitis in
1,018 patient years, yielding an overall peritonitis rate of
1 episode every 13 patient months [72]. In contrast to
this exceedingly high incidence Troidle et al. observed a
frequency of 5%. Increased age, increased length of
hospital stay, and hypoalbuminaemia may predispose
patients to the development of nosocomial peritonitis
[83]. In another study conducted by Bernardini et al. the
frequency of peritonitis was 0.34/year versus 0.52/year
(P=0.03) if patients received either gentamicin or
mupirocin at the exit site [84]. Zelenitsky et al. reported
1.37 episodes/patient-year in 1991, which decreased to
0.55 episode/patient-year in 1998 (P=0.02). The fre-
quencyofGram-positiveperitonitisdecreasedsignificantly
from 0.75 to 0.28 episode/patient-year during the same
period (P=0.02). Conversely, the occurrence of Gram-
negative peritonitis remained constant at approximately
0.16 episode/patient-year (P=0.28). Staphylococcus
epidermidis and Staphylococcus aureus were the most
common causes of peritonitis, isolated in 27.8% and
19.3% of the culture-positive cases, respectively [85].
Comparing peritonitis rates between older (0.95/year)
and young (0.89/year) patients no differences were
found. The older patients, however, had a higher fre-
quency of S. epidermidis peritonitis (0.28/year vs.
0.13/year, p=0.0001). A study conducted by Chow et al.
reports 85 initial episodes of peritonitis in 897.1 patient-
years [86]. Levy et al. reviewed the clinical aspects of
peritonitis in which 83 patients treated with continuous
ambulatory or continuous cyclic peritoneal dialysis
between May 1978 and April 1988 were analysed. Peri-
tonitis occurred in 50 patients whose mean duration of
dialysis was 17.8 months, but not in 33 patients with a
meandurationofdialysisof10.4months.Themeantime
from starting dialysis to the first episode of peritonitis
was 7.1 months. The peritonitis rate was lower for con-
tinuous cyclic than for continuous ambulatory peritoneal
dialysis(1episodeper12.9vs.1episodeper8.1patient
months, respectively) [87].
Central venous catheters: long term
(Hickman/Broviac type catheters [HB]
catheters) and totally subcutaneously
implantable medical devices (Port
catheters [PAC])
Infectious complications are frequently encountered fol-
lowing tunnelled and cuffed long term Hickman-Broviac
type catheter insertion [88]. The catheters are employed
for application of antineoplastic medication in patients
with haemato-oncologic malignancies or albumin infu-
sions in patients with congenital nephrotic syndrome for
several months. Data indicate that administration of
parenteralnutritionisassociatedwitha2.5foldincreased
risk of infection in children who have CVAD in place for
cancer therapy. Also parenteral nutrition in patients with
short bowel syndrome has a similarly increased risk for
catheter associated infection [55], [89].
Investigations of the incidence of long term catheter re-
lated infections in large studies in an adult population
indicatearateof0.7–1.2per1,000catheterdays.These
figures may mislead the true incidence and the amount
of problem as the catheters are in place for a minimum
of 250 days. An average of 1 out of 4 patients will suffer
from a catheter related septicaemia. In children with
haemato-oncologic malignancies, frequencies of 2.15
infectiouscomplicationsper1,000catheterdays(1.4for
catheter insertion site and 0.75 bloodstream infections)
have been reported [90], [91]. An infection rate of 1.9
per 1,000 catheter days has been reported by the ONCO
KISS study in Germany relating to infections in 48% of
patients [92]. Rosenthal and Maki compared totally im-
plantable PORT catheters with Hickman catheters and
showed a significantly higher infection rate with the
Hickman catheter, 4.65 infections per 1,000 catheter
days as compared to 1.45 episodes per 1,000 Port days,
respectively [93]. Also, the time to first infection (52.3
daysversus108.82days),ashorterdurationofcatheter-
ization (140.75 versus 277.28 days) and hence a higher
frequency of removal due to mechanical complications
have been observed [91].
Haematopoetic stem cell transplantation was identified
as an independent risk factor for infection (odds ratio
–1.68). In another study, double-lumen (DL) or single-lu-
men (SL) Hickman-Broviac (HB) catheters, and single-lu-
men pressure-activated safety valve (PASV) catheters
were used and prospectively evaluated. Four types of
possible complication were defined: mechanical, throm-
botic, malfunctioning and infectious. Four hundred and
eighteen CVCs (180 single lumen -Hickman, 162 double
lumen Hickman and 76 pressure-activated safety valve
catheters) were inserted in 368 children, for a total of
107,012 catheter days at risk of complication. At least
onecomplicationoccurredwhileusing169ofthedevices
(40%): 46% of the double lumen Hickman, 46% of the
pressure-activatedsafetyvalvecathetersand33%ofthe
single lumen Hickman (P=0.02) catheters. Patients with
haematological malignancies or non-malignant diseases
had significantly more complications than those with
solid tumours (P <0.0001). Overall, 234 complications
were documented: 93 infectious (complication rate per
1,000catheterdaysatrisk(CR)=0.87),84malfunctioning
(CR=0.78),48mechanical(CR=0.45)andninethrombotic
(CR=0.08) episodes occured. Single lumen Hickman
cathetershadstatisticallyfewerinfectiouscomplications,
whilepressure-activatedsafetyvalvecathetershadmore
mechanical complications [94].
InPort-cathetersthefrequencyofinfectionisconsiderably
lower and rates of 0.08–0.71 have been reported [95].
Port catheters are infected mainly on the inside (80%).
Pocketinfectionontheoutsideoftheimplantabledevice
has been reported in 10% and on both in 10%. In a
carefully conducted survey the average Port-catheters
remained in situ for 232.9 (range 1–1298) days; the
complication rate due to infections was reported to be
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tion by thrombi, dislodgement of the catheter, ischemic
necrosis of the overlying skin and soft tissues due an
unfavourable design of the port chamber geometry and
last not least perforation of the bottom of the port
chamber have been observed [96]. In patients with Port-
catheters a premature explantation of the device has to
beperformedinasubstantialnumberofmainlypaediatric
patients[97].Significantdifferencesofprematureexplant-
ation between Hickman/Broviac type and Port-catheters
became evident at 400 days of catheter use. In spite of
that totally implantable Port-catheters in general may be
consideredthepreferreddeviceformostpaediatriconco-
logy and stem cell transplantation patients. In general
the Hickman-Broviac catheter and the totally implanted
port Port-catheter achieve safe and reliable venous ac-
cess in cancer patients [98].
Ventilator-associated pneumonia
Ventilator-associated pneumonia (VAP) is the most com-
monnosocomialinfectionfoundintheintensivecareunit
withareportedincidenceof9%to70%(average20–25%)
[15], [99], [100]. Data from a survey of all Austrian inten-
sive care units observed an incidence of 25.7/1,000
device days [54]. It is associated with major morbidity,
prolonged hospitalization, increased health care costs
andahighestattributablemortalityamongallnosocomial
infections ranging between 9–70% [101], [102], [103],
[104]. The aero-digestive tract above the vocal cords is
heavily colonized by bacteria; the lower respiratory tract
is normally free of bacteria. The major route for acquiring
VAPisthenasopharyngealandoropharyngealcolonization
by the endogenous flora or by pathogens acquired exo-
genously from the intensive care environment [105].
During critical illness and broad spectrum antibiotic cov-
erage contaminated respiratory equipment or hospital
water supply shifts the oral flora dramatically towards a
predominance of multi-resistant Gram-negative bacilli
and S. aureus. The stomach represents an additional
potential site of secondary colonization and reservoir of
nosocomial Gram-negative bacilli, when proton-pump in-
hibitors are used frequently.
Approximately 8 to 28% of patients receiving prolonged
(>48hours)mechanicalventilationwilldevelopventilator-
associated pneumonia (VAP) [106]. Prior colonization of
the aero-digestive tract is a common intermediary step
in the pathogenesis of ventilator-associated pneumonia
[107] and hence, a target for VAP prevention strategies.
Moreover, colonization is also a key intermediary step in
cross infection.
Consideringmanydifferentkindsofevidence,thereisno
debate that VAP is associated with a higher risk of death
than that due to the underlying disease alone, and new
approaches to improve the management of ventilator-
dependent patients are required. Therefore, studies in
thisfieldareneededtoevaluatemeaningfulandeffective
interventionslikeeffectiveprophylacticmeasures,earlier
diagnosis and treatment.
Specific data on the epidemiology and pathogenesis of
VAParemainlylimitedbythelackofstandardizedcriteria
for its unequivocal identification and the absence of uni-
versally accepted standards continues the controversy
about the adequacy and relevance of many studies on
VAP. However, it has already been questioned ten years
ago whether the study design itself may also influence
the results of studies on VAP [108]. Back in 1995, the
authorconductedameta-analysistotesttheassumption,
that intervention in a study population will eventually in-
crease the rates of colonization and infection in a control
population. The author demonstrated evidence that the
possibilityofcross-transmission,particularlytransmission
from intervention patients to control patients, exists in at
least some of the controlled trials. Disparities between
results of different studies in this field are explainable by
a range of potential possibilities, cross-infection being
one of them.
To investigate this finding more in depth, an ecological
study would be needed. This task was performed only
recently[109].Using42cohortstudygroupsastherefer-
ence standard, the prevalence of VAP was modeled in
two linear regressions, one with the control groups and
one with the intervention group of 96 VAP prevention
studies. This ecological study revealed that the rate of
VAP in the control groups of antibiotic prevention studies
was significantly higher than expected and that the pat-
terns of microbial isolates are unusual, suggesting the
occurrence of not recognized outbreaks of VAP in these
patients. The author concluded, that the possibility re-
mains that antibiotic based VAP prevention presents a
major cross infection hazard by the mechanism of selec-
tionandcross-transmissioninICUs.Italsowasconcluded
that being a control group of an antibiotic intervention
study with a placebo design is correlated with an inci-
dence of VAP above the expected. The implication of this
finding would be that an influence of cross transmission
in such designed studies is highly possible. Because this
influenceisinapparentinindividualstudies,conclusions
drawnfromsuchstudiesmightnotbecorrectandresults
of antibiotic prevention studies on VAP need to be re-ex-
amined.
However, this conclusion is problematic in view of antibi-
otic prevention or intervention studies. If an antibiotic is
appliedintheinterventiongroup,selectionandtransmis-
sionofmicroorganismsispossible.However,itisinherent
to this concept, that the selected organism itself will be
resistantagainsttheinterventioncompound,andhence,
will colonize and/or infect both, patients in the interven-
tion and control group. Therefore, the initial assumption
mighthavenooveralleffectonthedifferenceofincidence
of VAP caused by a specific, resistant organism in two
groups. In this respect it is not surprising that for in both
groups the average residuals indicate an increase in in-
cidence, contrary to the decrease suggested.
Endotracheal biofilm formation on the surface of a cath-
eter plays a contributory role in sustaining nasotracheal
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isms include anatomic airway barriers, cough reflexes,
mucociliary clearance [111], [112]. Below the terminal
bronchioles the cellular and humoral immune systems
areessentialcomponentsofhostdefence.Endotracheal
intubation bypasses completely natural host defences
as it suppresses the cough reflex, compromises mucocil-
iaryclearance,injuresthetrachealepithelialsurfaceand
provides direct conduit for rapid access of bacteria from
aboveintothelowerrespiratorytract[113].Contaminated
secretions pooled above the endotracheal cuff gain ac-
cesstothetracheaandinnerlumenoftheendotracheale
tube by traversing endotracheale tube cuff folds [114].
Amorphic particulate containing pathogens is propelled
into the distal airways by ventilator generated airflow or
tubing manipulations. Dislodgement of contaminated
biofilms by suction catheters has been suggested as ad-
ditional pathway in which the respiratory tract may be
inoculated. The combination of continuous exposure of
the respiratory tract to large numbers of potential patho-
gensthroughtheendotrachealtubeandfactorscomprom-
isinghostdefencee.g.criticalillness,co-morbiditiessuch
as chronic lung and heart diseases, malnutrition and the
barotraumathroughventilatorysupportandimmunosup-
pressive medication puts the mechanically ventilated
patient at great jeopardy of developing VAP [115], [116],
[117], [118].
TracheotomyhasbeenusedintheICUsettingtofacilitate
weaningfromtheventilator.Identicalpatho-mechanisms,
however, are present in patients with tracheotomy [119].
The majority of studies investigating early or later
tracheotomy indicate that the incidence of VAP is similar
in both groups and tracheotomy is not able to prevent
VAP. The presence of hyperthermia was identified as a
risk factor for both early and late tracheotomy. The incid-
ence of VAP in tracheotomised patients was 25.9% ap-
proximately1weekaftertracheotomy.Howevermortality
seemed to be lower in the patients with tracheotomy
[120].
In fact, VAP should be more accurately renamed endo-
tracheal-tube-related-pneumonia as more than 85% of
episodesofnosocomialpneumoniawereassociatedwith
some sort of respiratory assistance device including en-
dotracheale tubes, tracheotomy, nasal masks, nebuliza-
tion treatment [95].
VAP is not the only source of endotracheal tube related
nosocomial infection. Also nasotracheal intubation is a
risk for the development of nosocomial sinusitis and
contamination of the middle ear cavity. In a randomised
trial conducted by Rouby at al it was observed that radio-
logical sinusitis developed in 95% of patients intubated
via the nasotracheal path compared to 23% with an oral
tube [121], [122]. The entire tube is covered with a bac-
terial glycopolysaccharide revealing significant bacterial
growth in the majority of tubes examined. These organ-
isms are “milked” into the adjacent structure along the
nasopharyngeal path of the endotracheale tube by con-
tinuousmovementofthedevicewithartificialrespiration.
The heavily contaminated mucous membranes act as a
path for entry of pathogens into the systemic circulation.
Theincidenceofbacteraemiaandsepsisoriginatingfrom
the upper airways ranges between 12 and 18%.
A number of preventive measures have been designed
taking the described pathomechanisms into account.
There is preference of orotracheal versus nasotracheal
intubation, the use of non-invasive ventilation, and the
use of endotracheal tube with a dorsal lumen to allow
drainage or continuous subglottic suctioning of pooled
secretions above the cuff [123]. Strategies eradicating
theoropharyngealand/orintestinalmicrobialcolonization
such as chlorhexidine oral care, prophylactic aerosoliza-
tion of antimicrobials, selective aerodigestive mucosal
antimicrobial decontamination or the use of sucralfate
rather than H2 antagonists for stress ulcer prophylaxis as
well as measures to prevent aspiration by a semi-recum-
bent positioning have been shown to reduce the risk to
some degree in independent studies [124], [125].
Needless to say that hospital water has to be controlled
for Legionella pneumophilia. The use of medical devices
endowed with antimicrobial activity has not been invest-
igated yet fully but promising results could be expected
[126].
Nosocomialurinarytractinfections
A urinary tract infection (UTI) is a condition where one or
morestructuresintheurinarytractbecomeinfectedafter
bacteria overcome its strong natural defenses. In spite
ofthesedefenses,UTIsarethemostcommonofallinfec-
tionsandcanoccuratanytimeinthelifeofanindividual.
Infections of the urinary tract are the second most com-
mon accounting for 8–35% of all nosocomial infections
[15]. Millions of transurethral, suprapubic and neph-
rostomycathetersoruretheralstentsareusedeachyear.
This device subverts several host defences to allow bac-
terial entry at a cumulative rate of 3% to 10% per day i.e.
after1monthallpatientssufferfromabacteriuria[127].
Most frequently, bacteria from the urethral meatus as-
cend to the bladder between the mucosal and catheter
surfaces. Alternatively, bacteria may ascend within the
drainagesystemfollowingcontaminationofthedrainage
bag or disruption of the catheter tubing junction. The
presenceofanimplantabledeviceencouragestheorgan-
ism's persistent residence in the urinary tract. Catheter-
associated urinary tract infections are a frequent cause
of significant morbidity. Nosocomial urinary tract infec-
tions are closely linked to unalterable host factors such
as age, female sex, and debilitating disease. There are
also dietary factors affecting the susceptibility to urinary
tract infection by alteration of the bacterial composition
of stool or alkalinization of the urine favoring struvite
formation [128].
The consequences of nosocomial urinary tract infections
are generally less severe than for other types of nosoco-
mial infections and catheter-associated bacteriurias are
frequentlyasymptomatic.Thecomplicationsinshort-term
catheterized patients include fever, acute pyelonephritis,
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are at risk for these complications with catheter obstruc-
tion, urinary tract stones, local periurinary infections,
chronic renal inflammation, chronic pyelonephritis, and,
over years, bladder cancer. The prolongation of duration
of admission is generally 3 days [129], [130], [131].
Risk factors for bacteriuria are
• Duration of catheter placement >14 days
• No systemic antibiotics
• Female gender, age >65
• Serum Kreatinin >2 mg/dl
• Diabetes mellitus
• Severe, rapidly fatal underlying disorder
• Lackofaseptictechniquesduringcatheterplacement
• Contamination of collecting bag
• Periurethral contamination with pathogenic microor-
ganisms
Recent attention has appropriately focused on biofilm
formationbyureaformingmicroorganismsonthecatheter
surface because biofilm and hence the incrustation with
calciumandmagnesiumstruviteshasimportantimplica-
tions for the pathogenesis, treatment, and prevention of
catheter-related infection.
Sepsis (4%) is predominately seen with obstruction of an
indwellingtransurethralcatheterandresultsinamortality
of 13% [132]. Risk factor for nosocomial bacteraemia
and sepsis originating in the urinary tract are
• Male gender, age >65 a
• Infection with Serratia marcescens
• Non-infectious disorders of the urinary tract (Nephro-
lithiasis, Prostata Ca)
Transurethralcatheterizationisgenerallyassociatedwith
a higher incidence of urinary tract infections than supra-
pubic catheterization; however, suprapubic catheteriza-
tion is associated with other disadvantages such as
higher costs and a more difficult technique, and at the
moment there is no consensus about the use of both
catheter systems [133]. There is no difference in the in-
cidence of a urinary tract infection between the suprapu-
bic group (n=9/75; 12%) and the transurethral group
(n=8/71; 11%) [134]. The incidence of a urinary tract
infection between a suprapubic catheter and a transur-
ethralcatheterinpatientsundergoingmajorsurgerywas
not different. A potential advantage of the suprapubic
catheter(reductionofurinarytractinfections)isprobably
partly negated, because transurethral catheters were
used if re-catheterization was indicated during the post-
operative stay or due to complications.
Preventive measures for nosocomial urinary tract infec-
tions have been investigated. Systemic antibiotics have
not been effective. Their use results in infection of the
bladder with resistant organisms, including Candida sp.
[135]. This and the effect of side effects on the patient
and emergence of resistant bacteria in the medical unit
haveledmostauthoritiestoconcludethatantibioticsare
not useful for prevention of bacteriuria, nor for treatment
of bacteriuria in the asymptomatic catheterized patient.
The closed catheter system has been a magnificent step
forward in the prevention of catheter-associated bacter-
iuria. Indeed, only two catheter principles are universally
recommended: keep the closed catheter system closed
andremovethecatheterassoonaspossible[136].Most
modifications of the closed catheter system have not
improved markedly on its ability to postpone bacteriuria.
Prevention of postoperative bacteriuria must be based
on careful haemostasis, prevention of postoperative
catheter disconnections, and limitation of the duration
of postoperative catheterization. The frequency of post-
operative bacteriuria after transurethral resection of the
prostate is raising the question of the choice and/or
durationofprophylacticantibiotics.Antimicrobialprophy-
laxis frequently leads to outgrowth of resistant bacterial
strainsthataredifficulttoeradicate.However,antimicro-
bial prophylaxis warrants consideration for high-risk im-
munocompromised patients who are catheterized for a
short time. If bacteriuria occurs prior to removal of the
catheter, the patient should be treated with appropriate
antimicrobial therapy.
Infections of other implantable
medical devices
External and internal ventricular
drainage systems
Since four decades, neurosurgeons have inserted pros-
thetic devices into the central nervous system [137],
[138]. Drainage systems are either implanted for diver-
sionofcerebrospinalfluidinpatientswithhydrocephalus
but also for emergency treatment of an increased intra-
cranial pressure. A second major indication for insertion
of a CNS prosthetic device is continuous intracranial
pressure monitoring. This and external ventricular drain-
age systems in critically ill patients are of particular con-
cernbecauseofthethreattheyposetocerebralfunction.
External drainage and pressure monitoring systems, to
lesserdegreeinternalCSFshuntsmayleadtoventriculit-
is,meningitisandventricularcompartmentalisation.CNS
infections are complicated by deterioration of mental
capacity and can also be especially lethal [139].
Difficultiesariseastheoffendingorganismsarefrequently
multi-resistant nosocomial pathogens for which only a
limitedspectrumofantibioticssubstancesisactive.Anti-
biotics like glycopeptides and aminoglycosides do not
penetrate the blood-brain barrier in bactericidal concen-
trations [140].
The frequency of infected external ventricular drainage
systems is in a range between 6 and 15% with a mean
of 12%. Studies have demonstrated that prophylactic
antibiotic e.g. quinolones do not reduce the incidence of
device related infections [141].
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Prosthetic joint implantation is among the most remark-
ableadvancesinsurgerytooccurduringthelastdecade.
However, because of the devastating results and large
number of prosthetic procedures, prosthetic infection
remains a major challenge. Although the results of this
procedure are usually highly satisfactory, infection is re-
cognized as a serious cause of postoperative morbidity
andprosthesisfailure.Infectionsoftheprosthesisoccurs
only in a small proportion of patients, however, this
dreaded complication results in major morbidity due to
pain, lifetime bedridden, failure and loss of prosthesis,
requirement of re-operation and in some instances loss
of limb or life [142], [143], [144]. Successful treatment
is difficult and usually requires both, multiple operative
procedures and antimicrobial therapy in excess of three
months[145].Inspiteofthesemeasures,thetherapeutic
outcome is less than satisfactory.
Two major mechanisms by which microorganisms cause
prosthetic joint infections have been postulated. Micro-
organisms may colonize the prosthesis at the time of
implantation either through direct inoculation or as a
result of airborne contamination of the wound or device
[146]. Alternatively, microorganisms may reach a previ-
ously sterile implant either through haematogenous
seeding during a bacteraemia or from an adjacent focus
of infection [147]. The distinction between the two
mechanisms may be difficult due to the long latency
period between onset of infection and the appearance
of symptoms. Despite this controversy it is believed hat
the majority of prosthetic joint infections are acquired in
the operating room.
Adoption of advanced methods for clinical and microbio-
logicdiagnosisandeffectiveprophylacticmeasuressuch
as improved operating room techniques and systemic
antibiotics, the prosthetic infection rate for artificial joint
procedures has been favourably influenced [148]. Ad-
vances in regard to the prediction of a successful antimi-
crobial therapy have been achieved [149]. Prosthetic
joint infections occur in approximately 1.5%–2.5% of all
primary hip or knee arthroplasties. The mortality rate at-
tributed to prosthetic joint infection may be as high as
2.5% [150]. Advanced age is one of the greatest a risk
factors for prosthetic joint infection as well a underlying
disorders such as rheumatoid arthritis; corticosteroid
treatment,diabetesmellitusandmalignancies.Inpatients
olderthan80yearsofageanincidenceof9.5%hasbeen
reported. Haemophilia, in contrast, was identified as a
singleindependentriskfactorin16%ofaffectedpatients.
Rheumatoidarthritismaybeariskfactorforlateprosthet-
ic joint infections in older prosthetic joint patients under-
going invasive dental procedure in the posterior oral
cavity [151], [152]. Fife infected prosthetic joints have
beenreportedin4,010jointyearsofHIVpositivepatients,
and HIV seemed to be no predisposing factor [153]. A
previous history of septic arthritis or osteomyelitis has
been identified as independent risk factor.
The treatment of an already infected prosthetic joint is
difficult. Debridement and retention of the prosthesis is
the initial treatment modality. This has been performed
in 30 patients with 33 Staphylococcus aureus prosthetic
jointinfectionswhopresentedtotheMayoClinicbetween
1980 and 1991. Treatment failure, defined as relapse
of S. aureus prosthetic joint infection or occurrence of
culture-negativeprostheticjointinfectionduringcontinu-
ous anti-staphylococcal therapy, occurred in 21 of 33
prosthetic joints [154]. The overall infection rate (when
late sepsis up to an observation period of 4 years is in-
cluded) remains at over 1%, and will likely increase as
the life expectancy of implants is increased and patients
are followed up longer. Data from Spain report an incid-
ence of 5.1% [155]. However, the sole correction using
ASA scoring led to an uncorrected SSI frequency of 5.8
per 100 surgeries. In the NNIS risk group 0 using correc-
ted ASA scores, the frequency was 4.5 per 100 surgeries
[156].
Anearlydiagnosismaysometimesbedifficultduetolack
of significant inflammatory signs. Low-grade infections
in particular are difficult to distinguish from aseptic fail-
ure, often presenting only with early loosening and per-
sisting pain, or no clinical signs of infection at all. The
most favoured approach is the two-stage delayed re-im-
plantation, in which patients receive specific antibiotic
therapyfor6weeksormore.Severaladditionalantibiotics
otherthanvancomycinareavailableformethicillin-resist-
ant staphylococcal infection, but these are still unproven
in the treatment of osteomyelitis or prosthetic joint infec-
tion [157].
Pacemaker Infections
The implantation of a pacemaker has become an every-
daymedicalprocedure.Newindicationsareunderevalu-
ation.However,itshouldberecalledthatthisisasurgical
interventionwithimplantationofprosthesiswithpossible
complications[158].Thereareearlycomplicationswhich
occur in the first 6 weeks after implantation and late
complications.Theiroverallincidenceisunderestimated
(up to 7%) as well as their seriousness [159]. The repor-
ted incidence of pacing system-related infections varies
widely, and the roles of leads and blood cultures remain
poorly defined. During the previous decade, there was a
significantincreaseinboth,cardiacdeviceimplantations,
and infections in elderly patients, although the increase
in the frequency of device infections was substantially
higher. The incidence of end point events in control
groups ranged from 0% to 12%. The meta-analysis sug-
gested a consistent protective effect of antibiotic pre-
treatment (P=.0046; common odds ratio: 0.256, 95%
confidence interval: 0.10 to 0.656). This incidence was
significantlyhigherthaninpatientsyoungerthan40years
at first implantation without congenital heart disease
(2.3%) and in patients older than 40 years (1.2%,
P<0.001) (5%) [160]. The majority of pacemaker infec-
tionsareresponsibleforpacemakerdysfunction,therisk
ofwhichisproportionaltothedependenceofthepatient
11/19 GMS Krankenhaushygiene Interdisziplinär 2011, Vol. 6(1), ISSN 1863-5245
Guggenbichler et al.: Incidence and clinical implication of nosocomial infections ...onpermanentcardiacpacing[161].Theoverallincidence
of late complications was significantly lower after first
implantation of a permanent pacemaker (34 cases,
complication rate 1.4%, 95% confidence interval 0.9% to
1.9%) than after elective unit replacement (16 cases,
complication rate 6.5% (3.3% to 9.7%) [162], [163]. The
highestincidenceofdevicerelatedinfectionwasinheart
transplant recipients with 20% [164], [165].
Pacemakerendocarditisisararebutseriouscomplication
[166]. Clinical characteristics and outcome were retro-
spectively studied in 38 patients with 44 episodes of
pacemaker infective endocarditis in Goteborg, during
1984–2001. Transthoracic echocardiography showed
vegetationin4/22(18%)episodesandtransoesophageal
echocardiography in 22/33 (67%). Staphylococci were
isolated in 66% of blood cultures. Overall mortality was
24% after a mean follow-up period of 22 +/- 4 months
(range 1 to 88) [167]. The frequency of prosthetic infect-
ive endocarditis varies according to the criteria used in
the literature, ranging from 0.4 to 1.3% for early infective
endocarditis, with an annual linear risk of late infective
endocarditis of 0.5% [168].
Regardlessoftheclinicalpresentation,theextravascular
and intravascular body of the lead is infected, even when
the infection is local. More than one micro-organism may
beimplicated.Bacteriologicanalysesmustbeperformed
on several segments of each implanted lead. More than
2 positive blood cultures are a reliable clinical criterion
for the diagnosis of pacemaker lead-related infection,
but blood cultures alone are an insensitive method to
identify the cause of infection. Up to 50% of microorgan-
isms isolated in a single blood culture are also recovered
inleadcultures.Recurrentundiagnosedsepticpulmonary
embolisms from pacemaker lead vegetations inducing
chronic cor pulmonale with serious pulmonary arterial
hypertension [169].
Vascular graft infections
Technological advances in artificial conduits have made
vascular reconstructive surgery to any accessible artery
possible [170]. While infection rates for autologous ven-
ous and arterial grafts is low, there is a substantial in-
crease of infections in synthetic grafts with devastating
complications including sepsis, anastomotic disruption
withmasshaemorrhageandpseudoaneurysmformation,
graft thrombosis limb loss and high perioperative and
latemortality[171],[172].Infra-inguinalarterialprosthet-
ic graft is associated with substantial early mortality and
amputation rates [173]. Cryopreserved arterial allograft
in the management of major peripheral bypass graft in-
fectionsuggeststhatthistechniqueseemstobeauseful
option for treating one of the most dreaded vascular
complications [174].
Inacomprehensivesurvey410revascularizationproced-
ures(84aortic,41extraanatomic,and285infrainguinal)
were performed in patients with a mean age of 62 years
(range 43–88). The infection rate for the entire group
was 11.0% (45/410). Eighty percent (36/45) occurred
after infra-inguinal reconstructions and 64% (29/45) of
the infections involved the groin incision [175]. In a fur-
ther investigation in a smaller number of patients
pathomechanisms were studies: direct involvement of
the graft occurred in 67% (30/45), and 27% (12/45)
presented with anastomotic disruption [176]. The overall
mortality rate was 13 of 23 (56.5%) patients. The allo-
graft-relatedmortalityratewas5of23(22%).Theoverall
allograft-complicated patient rate was 15 of 23 (65%);
and 18 allograft ruptures in 12 patients and 8 allograft
thromboses in 6 patients were observed. The overall
amputation rate was 8.7% (2 of 23). Age of the recipient
older than 69 years (P=.02), positive preoperative
marked-leukocyte scanning (P=.04), and persistent
postoperative leukocytosis (P=0.03) were significant
variables associated with an increased risk of allograft-
related complications [177]. The rate however varies
considerably, optimal surgical techniques and perioper-
ative antibiotic prophylaxis seemed to stabilise the rate
at 1–5% [178]. During the last years the situation has
been complicated by the increased emergence of multi-
resistant microorganisms e.g. MRSA accounting now for
up to approximately 30% of clinical S. aureus isolates.
Special risk factors for this complication included mal-
nutrition, ongoing polymicrobial and fungal infections,
immunocompromised state, active cancer, steroid
treatment, and ongoing graft contamination from
gastrointestinal or pharyngeal leaks [179]. Risk factors
for sepsis after vascular surgery are substantially more
frequent in patients with lower limb arterial ischemia.
Pathogenicorganismswereisolatedfromtheskinpreop-
eratively significantly more frequently in patients with
ischemicrestpainandskinnecrosis(66%)thanrestpain
alone(21%)(P=0.0004)orclaudication/aneurysm(11%)
(P=0.0001) [180].
Dacron and polytetrafluorethylene (GoreTex) are the
synthetic graft materials best suitable. The heparin-bon-
ded ePTFE graft provided promising early patency and
limbsalvageresults,withnodevice-relatedcomplications,
in patients with occlusive vascular disease. Longer-term
and randomized studies are warranted to determine
whether this graft provides results superior to those
achieved with other prostheses, especially in patients at
increasedriskofearlygraftfailure.Furtherimprovements
e.g. with addition of silver nanoparticles are still possible
[181], [182].
Discussion
As noted in a position paper published in 2005 [1] ES-
CMIDisseriouslyconcernedaboutthefactthatalthough
it has been known for many years that antibiotic resist-
ance is becoming an increasing problem, there are very
few new antibiotics under development. The survey of
infection rates of various implantable biomaterials indic-
ates that this factor accounts for the majority of nosoco-
mial infections and must be considered an independent
risk factors. Certainly, additional factors e.g. prematurity
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mechanismse.g.neutropenia,diabetesmellitus,haemo-
philia, end stage renal disease and the administration of
certain drugs such as corticosteroides, and other immu-
nosuppressants.
The diagnosis of device related infections sometimes is
difficult.Diagnosiscanalsobesuggestedbythepresence
of a predisposing factor, febrile illness, and seemingly
unrelated underlying disorders. Even with problems not
directlysuggestiveofsepsisassociatedwithimplantable
biomaterial a device associated infection must be taken
intoconsideration.Variableandoftennon-specificclinical
and radiographic features of multiple, nodular infiltrates
inthelungarefoundinsepticpulmonaryembolism(SPE),
an uncommon disorder with an insidious onset and a
difficult diagnosis. Underlying condition predisposing for
SPE in a study with 14 patients included Lemmieres
syndrome (4/14), central venous catheter associated
infection(3/14)prostheticcardiacvalveinfection((2/14)
and pacemaker infection (2/14) [183].
The establishment of an infection control network within
a group of community hospitals was associated with
substantial decreases in nosocomial infection rates.
Standard surveillance methods, frequent data analysis
andfeedback,andinterventionsbasedonguidelinesand
protocols from the Centers for Disease Control and Pre-
vention were the principal strategies used to achieve
these reductions. In addition to lessening the adverse
clinical outcomes due to nosocomial infections, these
reductionssubstantiallydecreasedtheeconomicburden
ofinfection:thedeclineinnosocomialbloodstreaminfec-
tionsandventilator-associatedpneumoniaaloneyielded
potential savings of $ 578,307 to $ 2,195,954 per year
at the study hospitals [184].
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Erratum
In the section "Central venous catheters: intermediate
(Sheldon)" the indication "(11.97/10,000 days,
28.81/10,000 haemodialysis procedures)" has been
changedin"(11.97/1,000days,28.81/1,000haemodia-
lysis procedures)".
The text has been linguistically improved.
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